Evidence map›Paper›PMID 30406211›Full record

ArticleClinical and translational radiation oncology2019

The FGF1/CPP-C chimera protein protects against intestinal adverse effects of C-ion radiotherapy without exacerbating pancreatic carcinoma.

Mitsuko Kawano, Taichi Miura, Mayumi Fujita, Sachiko Koike, Kaori Imadome, Atsuko Ishikawa, Takeshi Yasuda, Toru Imamura, Takashi Imai, Fumiaki Nakayama

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Mitsuko KawanoNational Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Taichi MiuraNational Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Mayumi FujitaNational Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Sachiko KoikeNational Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Kaori ImadomeNational Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Atsuko IshikawaNational Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Takeshi YasudaNational Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Toru ImamuraNational Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Takashi ImaiNational Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Fumiaki NakayamaNational Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
National Institutes for Quantum Science and Technology · JPTokyo University of Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeCarbon ion (C-ion) beams are concentrated to irradiate pancreatic carcinoma in the upper abdomen; however, this radiotherapy potentially causes adverse reactions in the gastrointestinal tract. FGF1 is a candidate radioprotector for radiation-induced intestinal damage, but may promote the malignancy of pancreatic cancer. An FGF1/CPP-C chimeric protein was created to enhance the intracellular signaling mode of FGF1 instead of FGFR signaling. The present study investigated the effects of FGF1/CPP-C on the intestinal adverse reactions of C-ion radiotherapy as well as its influence on the malignancy of pancreatic cancer. MATERIALS AND

methodsFGF1/CPP-C was administered intraperitoneally to BALB/c mice without heparin 12 h before total body irradiation (TBI) with low-LET C-ion (17 keV/μm) at 6-8 Gy. Several radioprotective effects were examined in the jejunum. The invasion and migration of the human pancreatic carcinoma cell lines MIAPaCa-2 and PANC-1 were assessed using Boyden chambers after cultures with FGF1/CPP-C.

resultsThe FGF1/CPP-C treatment promoted crypt survival after C-ion irradiation at 7-8 Gy significantly more than the FGF1 treatment. FGF1/CPP-C also inhibited C-ion radiotherapy-induced apoptosis and reduced γH2AX foci in crypt cells more than FGF1. However, FGF1/CPP-C inhibited the downstream signaling pathways of FGFRs and suppressed the activation of cell-cycle regulatory molecules in the intestine until 4 h after TBI. Furthermore, IEC6 cells were arrested in G2M after cultures with FGF1/CPP-C or FGF1, suggesting that DNA repair after irradiation is promoted by FGF1/CPP-C-induced G2M arrest. In contrast, FGF1/CPP-C appeared to be internalized into MIAPaCa-2 and PANC-1 cells more efficiently than FGF1. Therefore, FGF1/CPP-C reduced the

conclusionThese results suggest that the intracellular signaling mode of FGF1/CPP-C attenuates the intestinal adverse effects of C-ion radiotherapy without enhancing the malignancy of pancreatic carcinoma.

Indexed as

Carbon ion radiotherapyCellular internalizationC-ion, carbon ionCPP, cell-penetrating peptideFGF1FGF, fibroblast growth factorFGFR, fibroblast growth factor receptorHIMAC, Heavy Ion Medical Accelerator in ChibaIntestinal adverse effectsPancreatic carcinomaRadioprotectorSOBP, spread-out Bragg peakTBI, total body irradiationTUNEL, terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick end labeling

Identifiers

PMID30406211
PMCPMC6215021
OpenAlexW2898255155

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.